(The author is a Reuters Breakingviews columnist. The opinions
expressed are her own.)
By Yawen Chen
HONG KONG, Jan 6 (Reuters Breakingviews) - The U.S. biotech
giant’s Covid-19 vaccines have inspired copycats in the People’s
Republic, where cities are scrambling to contain fresh
outbreaks. With foreign jabs yet to be approved, the $13 bln
Walvax looks promising. Feverish valuations leave little margin
for error.
Full view will be published shortly.
Follow @ywchen1 https://twitter.com/ywchen1 on Twitter
CONTEXT NEWS
- A Covid-19 vaccine using mRNA technology jointly developed
by Suzhou Abogen Biosciences, a research institute affiliated
with the Chinese military and Walvax Biotechnology, has obtained
approvals to begin Phase III clinical trials in Nepal, Mexico
and Indonesia, and is in the most advanced stage of clinical
development among vaccine candidates using mRNA technology that
China is researching, according to multiple statements by
Walvax.
- Suzhou Abogen Biosciences said it had completed a series
C+ fundraising round led by Softbank Vision Fund, Chimera Abu
Dubai, IMO ventures and others, in a WeChat post on its official
account dated Nov. 29.
- China’s northwestern city of Xian has been under lockdown
for two weeks after Covid-19 cases were found, while central
Chinese cities including Yuzhou and Zhengzhou in the province of
Henan imposed varying degrees of travel curbs, Reuters reported
on Jan. 5.
- Hong Kong will roll out a two-week ban on incoming flights
from eight countries, including the United States and Britain,
and tighten other restrictions, Hong Kong leader Carrie Lam told
reporters in a briefing on Jan. 5.
(Editing by Robyn Mak and Katrina Hamlin)
((For previous columns by the author, Reuters customers can
click on CHEN/
SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS https://bit.ly/BVsubscribe
| yawen.chen@thomsonreuters.com; Reuters Messaging:
yawen.chen.thomsonreuters.com@reuters.net))